Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Myonal 50mgMyonal

Eperisone hydrochloride

 

COMPOSITION

Each white, sugar-coated tablet contains 50 mg of eperisone hydrochloride.

 

[PRODUCT DESCRIPTION]

Myonal

INDICATIONS

Improvement of myotonic conditions caused by the following diseases :

Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain

 

Spastic paralysis caused by the following diseases :

Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, sequelae of surgical trauma (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorder, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies

 

DOSAGE AND ADMINISTRATION

The usual adult dosage for oral use is 3 tablets (150 mg of eperisone hydrochloride) daily in three divided doses after meals. The dosage may be adjusted depending on the patient's age and symptoms.

 

CONTRAINDICATIONS

(MYONAL is contraindicated in the following patients.)

Patients with a history of hypersensitivity to any ingredients of MYONAL.

 

PRECAUTIONS

1. Careful Administration (MYONAL should be administered with care in the following patients.)

(1) Patients with a history of drug hypersensitivity

(2) Patients with hepatic function disorder [MYONAL may aggravate hepatic function.]

 

2. Important Precautions

Weakness, light-headedness, sleepiness or other symptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.

 

[DRUG INTERACTIONS]

Precautions for coadministration (MYONAL should be administered with care when coadministered with the following drugs.)

 

[USE IN THE ELDERLY]

Since the elderly often have a physiological hypofunction, it is advisable to take measures, such as reduction in dosage under careful supervision.

 

[PREGNANCY AND LACTATION]

1. Use During Pregnancy MYONAL should only be used in pregnant women or women suspected of being pregnant, if the expected therapeutic benefits are evaluated to outweigh the possible risk of treatment. [The safety of MYONAL in pregnant women has not been established.] 2. Use During Lactation It is advisable to avoid the administration of MYONAL to nursing mothers. When MYONAL must be used, breast feeding should be discontinued during treatment. [It has been reported that MYONAL is excreted in breast milk in an animal study (in rats).]

 

[PEDIATRIC USE]

Safety in children has not been established (insufficient clinical experience).

 

[ADVERSE REACTIONS]

Adverse reactions were reported in 416 of 12,315 patients (3.38%).

(At the end of the reexamination period)

(1) Clinically significant adverse reactions (incidence unknown)

1) Shock and anaphylactoid reactions Since shock and anaphylactoid reactions may occur, patients should be carefully observed. In the event of symptoms such as redness, itching, urticaria, edema of the face or other parts and dyspnea etc., treatment should be discontinued and appropriate measures taken.

 

2) Oculo-muco-cutaneous syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Lyell syndrome)

Serious dermatopathy such as oculo-muco-cutaneous syndrome (Stevens-Johnson syndrome) or toxic epidermal necrolysis (Lyell syndrome) may occur. Patients should be carefully observed, treatment discontinued and appropriate measures taken, in the event of symptoms such as fever, erythema, blistering, itching, ocular congestion or stomatitis, etc.

 

(2) Other adverse reactions

 

5%>   ≥0.1%

<0.1%

Incidence unknown

Hepatic

 

Elevation of AST

(GOT), ALT(GPT)

and Al-P, etc.

 

Renal

 

Proteinuria and

Elevation of BUN etc.

 

 

Hematologic

 

Anemia

 

Hypersensitivity

Rash

Pruritus

erythema exudativum

multiforme

Psychoneurologic

Sleepiness, insomnia,

headache and numbness

in the extremities

 

Stiffness and tremor

in the extremities

 

Gastrointestinal

Nausea/vomiting,

anorexia, stomach discomfort,

abdominal pain, diarrhea,

constipation and thirst

Stomatitis and tremor

in the extremities

 

Urinary

 

Urinary retention,

urinary incontinence and

feeling of residual urine

 

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer